These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21755599)

  • 1. From high-throughput cell culture screening to mouse model: identification of new inhibitor classes against prion disease.
    Geissen M; Leidel F; Eiden M; Hirschberger T; Fast C; Bertsch U; Tavan P; Giese A; Kretzschmar H; Schatzl HM; Groschup MH
    ChemMedChem; 2011 Oct; 6(10):1928-37. PubMed ID: 21755599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of protease-resistant prion protein inhibitors in cell cultures infected with two strains of mouse and sheep scrapie.
    Kocisko DA; Engel AL; Harbuck K; Arnold KM; Olsen EA; Raymond LD; Vilette D; Caughey B
    Neurosci Lett; 2005 Nov; 388(2):106-11. PubMed ID: 16039063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Searching for anti-prion compounds: cell-based high-throughput in vitro assays and animal testing strategies.
    Kocisko DA; Caughey B
    Methods Enzymol; 2006; 412():223-34. PubMed ID: 17046661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and sub-cellular pathology of animal prion diseases: relationship between morphological changes, accumulation of abnormal prion protein and clinical disease.
    Jeffrey M; McGovern G; Sisó S; González L
    Acta Neuropathol; 2011 Jan; 121(1):113-34. PubMed ID: 20532540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biology of non-conventional transmissible agents or prions].
    Dormont D
    Rev Neurol (Paris); 1998 Feb; 154(2):142-51. PubMed ID: 9773035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperazine derivatives inhibit PrP/PrP(res) propagation in vitro and in vivo.
    Leidel F; Eiden M; Geissen M; Hirschberger T; Tavan P; Giese A; Kretzschmar HA; Schätzl H; Groschup MH
    Biochem Biophys Res Commun; 2014 Feb; 445(1):23-9. PubMed ID: 24502948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel generation of heparan sulfate mimetics for the treatment of prion diseases.
    Adjou KT; Simoneau S; Salès N; Lamoury F; Dormont D; Papy-Garcia D; Barritault D; Deslys JP; Lasmézas CI
    J Gen Virol; 2003 Sep; 84(Pt 9):2595-2603. PubMed ID: 12917481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies inhibit prion replication and delay the development of prion disease.
    White AR; Enever P; Tayebi M; Mushens R; Linehan J; Brandner S; Anstee D; Collinge J; Hawke S
    Nature; 2003 Mar; 422(6927):80-3. PubMed ID: 12621436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
    Nunziante M; Kehler C; Maas E; Kassack MU; Groschup M; Schätzl HM
    J Cell Sci; 2005 Nov; 118(Pt 21):4959-73. PubMed ID: 16219680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prion encephalopathies of animals and humans.
    Prusiner SB
    Dev Biol Stand; 1993; 80():31-44. PubMed ID: 8270114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prion protein self-interactions: a gateway to novel therapeutic strategies?
    Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
    Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-associated prion protein in the dental tissue of mice infected with scrapie.
    Okada H; Sakurai M; Yokoyama T; Mohri S
    J Comp Pathol; 2010; 143(2-3):218-22. PubMed ID: 20202648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and structure-activity relationship of indole-3-glyoxylamide libraries possessing highly potent activity in a cell line model of prion disease.
    Thompson MJ; Borsenberger V; Louth JC; Judd KE; Chen B
    J Med Chem; 2009 Dec; 52(23):7503-11. PubMed ID: 19842664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening Congo Red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells.
    Rudyk H; Vasiljevic S; Hennion RM; Birkett CR; Hope J; Gilbert IH
    J Gen Virol; 2000 Apr; 81(Pt 4):1155-64. PubMed ID: 10725446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products.
    Kocisko DA; Baron GS; Rubenstein R; Chen J; Kuizon S; Caughey B
    J Virol; 2003 Oct; 77(19):10288-94. PubMed ID: 12970413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biology of prions causing infectious and genetic encephalopathies of humans as well as scrapie of sheep and BSE of cattle.
    Prusiner SB
    Dev Biol Stand; 1991; 75():55-74. PubMed ID: 1686599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prion protein and the scrapie agent: in vitro studies in infected neuroblastoma cells.
    Priola SA; Caughey B; Raymond GJ; Chesebro B
    Infect Agents Dis; 1994; 3(2-3):54-8. PubMed ID: 7812655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prions can infect primary cultured neurons and astrocytes and promote neuronal cell death.
    Cronier S; Laude H; Peyrin JM
    Proc Natl Acad Sci U S A; 2004 Aug; 101(33):12271-6. PubMed ID: 15302929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific inhibition of pathological prion protein accumulation by small interfering RNAs.
    Daude N; Marella M; Chabry J
    J Cell Sci; 2003 Jul; 116(Pt 13):2775-9. PubMed ID: 12759373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of new cell culture inhibitors of protease-resistant prion protein against scrapie infection in mice.
    Kocisko DA; Morrey JD; Race RE; Chen J; Caughey B
    J Gen Virol; 2004 Aug; 85(Pt 8):2479-2483. PubMed ID: 15269390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.